World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
112
Citations
101235
World Ranking
5033
National Ranking
193

Overview

John B. A. G. Haanen is affiliated with the Antoni van Leeuwenhoek Hospital in the Netherlands. Their academic contributions primarily focus on oncology within the broader field of medicine. The main areas of study include oncology, molecular biology, immunology, pulmonary and respiratory medicine, and radiology-related imaging techniques.

Their research covers several key topics including:

  • Cancer immunotherapy and biomarkers
  • CAR-T cell therapy research
  • Immunotherapy and immune responses
  • Cutaneous melanoma detection and management
  • Melanoma and MAPK pathways
  • Renal cell carcinoma treatment
  • Cancer genomics and diagnostics

John B. A. G. Haanen has published extensively in a range of scientific journals. Frequent publication venues for their work include:

  • Journal of Clinical Oncology
  • Annals of Oncology
  • European Journal of Cancer
  • ESMO Open
  • Nature Medicine

Some of their recent notable papers are:

  • Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up, 2022, Annals of Oncology
  • Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers, 2020, Nature Medicine

Among their frequent co-authors are:

  • Christian U. Blank
  • Ellen Kapiteijn
  • Karijn P.M. Suijkerbuijk
  • Geke A.P. Hospers
  • Maureen J.B. Aarts

The scientist's work contributes notably to the areas of cancer treatment and immunotherapy, addressing both molecular and clinical aspects. Their research spans from understanding immunological mechanisms to clinical management of advanced cancers including melanoma and renal cell carcinoma.

Best Publications

  • Improved Survival with Ipilimumab in Patients with Metastatic Melanoma.

    F. Stephen Hodi;Steven J. O'Day;David F. McDermott;Robert W. Weber

  • Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation

    Paul B. Chapman;Axel Hauschild;Caroline Robert;John B. Haanen

  • Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma.

    James Larkin;Vanna Chiarion-Sileni;Rene Gonzalez;Jean Jacques Grob

  • Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma

    Jedd D. Wolchok;Vanna Chiarion-Sileni;Rene Gonzalez;Piotr Rutkowski

  • Five-year survival with combined nivolumab and ipilimumab in advanced melanoma: New England Journal of Medicine

    J. Larkin;V. Chiarion-Sileni;R. Gonzalez;J.-J. Grob

  • Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma

    Robert J. Motzer;Konstantin Penkov;John Haanen;Brian Rini

  • Interleukin 10 (IL-10) and viral IL-10 strongly reduce antigen-specific human T cell proliferation by diminishing the antigen-presenting capacity of monocytes via downregulation of class II major histocompatibility complex expression.

    R de Waal Malefyt;J Haanen;H Spits;M G Roncarolo

  • Combined BRAF and MEK Inhibition versus BRAF Inhibition Alone in Melanoma

    G.V. Long;D. Stroyakovskiy;H. Gogas;E. Levchenko

  • Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial

    Georgina V. Long;Georgina V. Long;Daniil Stroyakovskiy;Helen Gogas;Evgeny Levchenko

  • Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers.

    Myriam Chalabi;Lorenzo F Fanchi;Krijn K Dijkstra;José G Van den Berg

  • Safety and efficacy of vemurafenib in BRAFV600E and BRAFV600K mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study

    Grant A McArthur;Paul B Chapman;Caroline Robert;James Larkin

  • Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma.

    Caroline Robert;Jean J Grob;Daniil Stroyakovskiy;Boguslawa Karaszewska

  • Dysfunctional CD8 T Cells Form a Proliferative, Dynamically Regulated Compartment within Human Melanoma

    Hanjie Li;Anne M. van der Leun;Ido Yofe;Yaniv Lubling

  • Generation of Tumor-Reactive T Cells by Co-culture of Peripheral Blood Lymphocytes and Tumor Organoids

    Krijn K Dijkstra;Chiara M Cattaneo;Fleur Weeber;Myriam Chalabi

  • Tumor Exome Analysis Reveals Neoantigen-Specific T-Cell Reactivity in an Ipilimumab-Responsive Melanoma

    Nienke van Rooij;Marit M. van Buuren;Daisy Philips;Arno Velds

  • Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma

    Chong Sun;Liqin Wang;Sidong Huang;Guus J. J. E. Heynen

  • Phase III Randomized Clinical Trial Comparing Tremelimumab With Standard-of-Care Chemotherapy in Patients With Advanced Melanoma

    Antoni Ribas;Richard Kefford;Margaret A. Marshall;Cornelis J.A. Punt

  • The “cancer immunogram”

    Christian U. Blank;John B. Haanen;Antoni Ribas;Ton N. Schumacher

  • Immune induction strategies in metastatic triple-negative breast cancer to enhance the sensitivity to PD-1 blockade: the TONIC trial.

    Leonie Voorwerk;Maarten Slagter;Hugo M. Horlings;Karolina Sikorska

  • Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma

    Christian U. Blank;Elisa A. Rozeman;Lorenzo F. Fanchi;Karolina Sikorska

Frequent Co-Authors

Ton N. M. Schumacher
Ton N. M. Schumacher Antoni van Leeuwenhoek Hospital
Christian U. Blank
Christian U. Blank Antoni van Leeuwenhoek Hospital
Jos H. Beijnen
Jos H. Beijnen Utrecht University
James Larkin
James Larkin Royal Marsden NHS Foundation Trust
Dirk Schadendorf
Dirk Schadendorf University of Duisburg-Essen
Reinhard Dummer
Reinhard Dummer University of Zurich
Simon Horenblas
Simon Horenblas Antoni van Leeuwenhoek Hospital
Caroline Robert
Caroline Robert University of Paris-Saclay
Paul Lorigan
Paul Lorigan University of Manchester
Antoni Ribas
Antoni Ribas University of California, Los Angeles

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring a medical career doesn't always mean following the path to becoming a physician. There are many online degree options and unique career pathways for those passionate about healthcare. For students eager to advance quickly, fast track LPN programs provide a streamlined route into nursing, allowing you to start working sooner.

For registered nurses aiming to take their education further, DNP online programs offer a flexible way to earn a Doctor of Nursing Practice without sacrificing your current job. Those interested in mental health might consider the fastest psychiatric nurse practitioner program to quickly specialize in this vital field.

Additionally, for individuals who see themselves in leadership or administrative roles, enrolling in a health administration degree online can open doors to behind-the-scenes positions that are critical to hospital and clinic operations. These online programs offer flexibility, affordability, and the chance to make a meaningful impact on the healthcare system.

Best Scientists Citing John B. A. G. Haanen

Trending Scientists

Recently Published Articles